MedTrace Logo

Efficacy of Ivermectin in COVID-19

NCT04392713 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-05-19

No results posted yet for this study

Summary

It is a randomized controlled trial to assess the efficacy of Ivermectin in COVID-19. Patient recruited will be assigned to two groups one group will be given ivermectin with standard chloroquine regimen and the other group will be receiving chloroquine only. Out come will be recorded by documenting PCR reports at 48, 96 and 144 hours.

Conditions

Interventions

DRUG

Ivermectin 6 MG Oral Tablet (2 tablets)

12 mg single dose of Ivermectin will be given to intervention arm

Sponsors & Collaborators

  • Combined Military Hospital, Pakistan

    lead OTHER

Principal Investigators

  • Karamat Hu Bukhari, FCPS MED · Combined military hospital lahore

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-15
Primary Completion
2020-07-31
Completion
2020-07-31

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04392713 on ClinicalTrials.gov